MCP-1 Monoclonal Antibody, PeproTech®

Product Details	
Size	500 µg
Species Reactivity	Human
Published Species	Bovine, Human, Mouse
Host/Isotype	Mouse
Class	Monoclonal
Type	Antibody
Conjugate	Unconjugated
Immunogen	E.coli-derived Recombinant Human MCP-1 (CCL2)
Form	Lyophilized
Purification	Protein A
Storage buffer	PBS
Contains	no preservative
Storage conditions	-20°C

Applications	Tested Dilution	Publications
Western Blot (WB)	0.20-0.40 µg/mL	-
Immunocytochemistry (ICC/IF)	-	1 Publication
ELISA (ELISA)	1.0-2.0 µg/mL	9 Publications
Neutralization (Neu)	-	3 Publications

Product Specific Information

AA Sequence of recombinant protein: QPDAINAPVT CCYNFTNRKI SVQRLASYRR ITSSKCPKEA VIFKTIVAKE ICADPKQKWV QDSMDHLDKQ TQTPKT.

Preparation: Produced in BALB/c mice immunized with highly pure Recombinant Human MCP-1 (CCL2). Anti-Human MCP-1 (CCL2)-specific antibody was purified from cell culture supernatant by Protein A affinity chromatography.

Sandwich ELISA: Assuming 100 µL/well, a concentration of 1.0-2.0 µg/mL of this antibody will detect at least 100 pg/mL of Recombinant Human MCP-1 (CCL2) when used with PeproTech Biotinylated Antigen Affinity Purified Anti-Human MCP-1 (CCL2) (500-P34BT) as the detection antibody at a concentration of approximately 0.5-1.0 µg/mL.

Western Blot: To detect Human MCP-1 (CCL2) by Western Blot analysis this antibody can be used at a concentration of 0.20-0.40 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human MCP-1 (CCL2) is 1.0-2.0 ng/lane under reducing conditions and 0.25-0.50 ng/lane under non-reducing conditions.

Product Images For MCP-1 Monoclonal Antibody, PeproTech®



MCP-1 Antibody (500-M71-500UG) in WB
Western Blot: To detect Human MCP-1 (CCL2) by Western Blot analysis MCP-1 Monoclonal Antibody (Product # 500-M71-500UG) can be used at a concentration of 0.20-0.40 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human MCP-1 (CCL2) is 1.0-2.0 ng/lane under reducing conditions and 0.25-0.50 ng/lane under non-reducing conditions.



MCP-1 Antibody (500-M71-500UG) in WB
Western Blot: To detect Human MCP-1 (CCL2) by Western Blot analysis MCP-1 Monoclonal Antibody (Product # 500-M71-500UG) can be used at a concentration of 0.20-0.40 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human MCP-1 (CCL2) is 1.0-2.0 ng/lane under reducing conditions and 0.25-0.50 ng/lane under non-reducing conditions.



MCP-1 Antibody (500-M71-500UG) in ELISA
Sandwich ELISA: Assuming 100 µL/well, a concentration of 1.0-2.0 µg/mL of MCP-1 Monoclonal Antibody (Product # 500-M71-500UG) will detect at least 100 pg/mL of Recombinant Human MCP-1 (CCL2) when used with PeproTech MCP-1 Polyclonal Antibody, Biotin (Product # 500-P34BT-1MG) as the detection antibody at a concentration of approximately 0.5-1.0 µg/mL.

13 References

Immunocytochemistry (1)

Neoplasia (New York, N.Y.)

Breast cancer: coordinated regulation of CCL2 secretion by intracellular glycosaminoglycans and chemokine motifs.

"500-M71 was used in Immunocytochemistry-immunoflourescence to propose that targeting these chemokine regions may lead to reduced secretion of CCL2 by breast cancer cells (and potentially also by other malignant cells)."

Authors: Lebel-Haziv Y,Meshel T,Soria G,Yeheskel A,Mamon E,Ben-Baruch A

Year 2014

Species Human

ELISA (9)

Cancers

Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes.

"500-M71 was used in Enzyme-linked immunosorbent assay to investigate the role of WT-PD-L1 in triple-negative breast cancer."

Authors: Erlichman N,Baram T,Meshel T,Morein D,Da'adoosh B,Ben-Baruch A

Year 2022

Species Human

Frontiers in immunology

Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.

"500-M71 was used in Enzyme-linked immunosorbent assay to study the impact of tumor-stroma-inflammation networks on pro-metastatic phenotypes in triple-negative breast cancer (TNBC) to identify a novel tumor-stroma-inflammation networks that may promote TNBC aggressiveness by increasing the pro-malignancy potential of the TME and of the tumor cells themselves, and reveal key roles for CXCL8 in mediating these metastasis-promoting activities."

Authors: Liubomirski Y,Lerrer S,Meshel T,Rubinstein-Achiasaf L,Morein D,Wiemann S,Körner C,Ben-Baruch A

Year 2020

Species Human

View more ELISA references on thermofisher.cn

Neutralization (3)

Blood

Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages.

Authors: Fantuzzi L,Spadaro F,Vallanti G,Canini I,Ramoni C,Vicenzi E,Belardelli F,Poli G,Gessani S

Year 2003

Species Mouse

View more Neu references on thermofisher.cn

More applications with references on thermofisher.cn